Anders Holst, Acesion Pharma CEO

Ace­sion clinch­es $47M in Se­ries B raise to ad­vance pre­clin­i­cal car­diac ar­rhyth­mia can­di­date through PhII

Ace­sion Phar­ma has bagged 45 mil­lion eu­ros ($47 mil­lion) in an over­sub­scribed Se­ries B round. The fund­ing will sup­port its pre­clin­i­cal oral potas­si­um chan­nel in­hibitor for the pre­ven­tion of atri­al fib­ril­la­tion (AF) re­cur­rence through Phase II.

The Se­ries B was co-led by new US-based back­ers Canaan and Al­pha Wave, with sup­port from Glob­al BioAc­cess Fund and ex­ist­ing in­vestor No­vo Hold­ings.

The funds will be used to ad­vance Copen­hagen-based Ace­sion’s potas­si­um chan­nel in­hibitor for the chron­ic main­te­nance treat­ment of AF, dubbed AP31969, in­to the clin­ic and to the end of Phase II de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.